What is the recommended dose of Terbinafine for treating fungal infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Terbinafine Dosing for Fungal Infections

The recommended dose of terbinafine for treating fungal infections is 250 mg once daily, with duration varying by infection type: 6 weeks for fingernail infections and 12 weeks for toenail infections. 1

Dosing Guidelines by Infection Type

Onychomycosis (Nail Infections)

  • Adults: 250 mg once daily 1
    • Fingernail infections: 6 weeks
    • Toenail infections: 12 weeks

Tinea Capitis (Scalp Ringworm)

  • Children (weight-based dosing): 2, 3
    • < 20 kg: 62.5 mg daily for 2-4 weeks
    • 20-40 kg: 125 mg daily for 2-4 weeks
    • 40 kg: 250 mg daily for 2-4 weeks

Cutaneous and Lymphocutaneous Sporotrichosis

  • Adults: 500 mg twice daily 2
    • Treatment should continue for 2-4 weeks after all lesions have resolved (typically 3-6 months total)

Superficial Skin Infections (Tinea Corporis/Cruris/Pedis)

  • Adults: 250 mg once daily for 2 weeks 4, 5
  • Topical application: 1% formulation applied once or twice daily for up to 2 weeks 4

Efficacy and Mechanism of Action

Terbinafine is an allylamine antifungal agent with primarily fungicidal activity against a wide variety of dermatophytes, moulds, and certain dimorphic fungi 4. It has shown superior efficacy compared to other antifungals:

  • More effective than continuous or intermittent itraconazole in dermatophyte onychomycosis 4
  • Greater efficacy than griseofulvin in dermatophyte onychomycosis, tinea pedis, and tinea corporis/cruris 4
  • More effective than ketoconazole 200 mg/day in tinea corporis/cruris 4

Mycological cure rates typically exceed 80% for most superficial dermatophyte infections 4.

Special Considerations

Monitoring

  • Liver function tests should be performed before starting treatment, as terbinafine can cause liver problems that may lead to liver transplant or death 1
  • Monitor for taste or smell disturbances, which may be prolonged or permanent 1

Drug Interactions

Terbinafine is an inhibitor of CYP4502D6 isozyme and may interact with: 1

  • Antidepressants
  • Antihypertensives
  • Cardiac medications
  • Desipramine
  • Caffeine
  • Cyclosporine
  • Fluconazole
  • Rifampin
  • Cimetidine

Alternative Dosing Regimens

For onychomycosis, a pulsed regimen (500 mg daily for 1 week every 4 weeks, over 16 weeks) has shown similar efficacy to continuous dosing with potentially lower cost and better convenience 6.

Common Pitfalls and Caveats

  1. Confirm diagnosis before treatment: Laboratory diagnosis through microscopy and culture is essential before initiating treatment 3

  2. Species-specific efficacy: Terbinafine is more effective against Trichophyton species than Microsporum species 2. For Microsporum infections, griseofulvin may be more appropriate.

  3. Treatment failure considerations: 3

    • Poor compliance
    • Suboptimal absorption
    • Immunosuppression
    • Dermatophyte resistance
    • Inadequate treatment duration
  4. Adverse effects to monitor: 1

    • Liver problems (monitor liver enzymes)
    • Taste or smell disturbances
    • Depressive symptoms
    • Severe neutropenia
    • Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)

Terbinafine is generally well-tolerated with relatively low potential for drug interactions compared to azole antifungals, making it a first-line treatment option for many fungal infections, particularly dermatophyte onychomycosis 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.